

28<sup>th</sup> January, 2026

**BSE Limited**

P.J. Towers, Dalal Street, Fort,  
Mumbai- 400 001  
BSE scrip code: 543635

**National Stock Exchange of India Limited**

Exchange Plaza, Bandra-Kurla Complex,  
Bandra (East), Mumbai – 400 051  
NSE symbol: PPLPHARMA

**Sub: Press Release and Investor Presentation – Unaudited Financial Results  
(Standalone & Consolidated) of the Company for the quarter and nine months ended  
31<sup>st</sup> December, 2025**

Dear Sir / Madam,

Further to our intimation made earlier with regard to Unaudited Financial Results (Standalone & Consolidated) of the Company for the quarter and nine months ended 31<sup>st</sup> December, 2025 ('Financial Results'), please find enclosed herewith the Press Release and the Investor Presentation on the Financial Results.

The above information is also available on the website of the Company at <https://www.piramalpharma.com/>.

You are requested to kindly take the above information on record.

Yours truly,

For **Piramal Pharma Limited**

**Tanya Sanish**  
**Company Secretary**

Encl.: a/a

PRESS RELEASE

## Piramal Pharma Limited Announces Results for Q3 and 9M FY26

**Mumbai, India | January 28, 2026:** Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Third Quarter (Q3) and Nine Month (9M) ended 31<sup>st</sup> December 2025.

### Consolidated Financial Highlights

(in ₹ Crores or as stated)

Particulars	Q3FY26	Q3FY25	YoY %	9MFY26	9MFY25	YoY %
<b>Revenue from Operations</b>	<b>2,140</b>	<b>2,204</b>	<b>(3)%</b>	<b>6,117</b>	<b>6,397</b>	<b>(4)%</b>
CDMO	1,166	1,278	(9)%	3,207	3,659	(12)%
CHG	668	654	2%	1,948	1,928	1%
PCH	334	278	20%	954	819	16%
<b>EBITDA</b>	<b>239</b>	<b>350</b>	<b>(32)%</b>	<b>628</b>	<b>977</b>	<b>(36)%</b>
<b>EBITDA Margin</b>	<b>11%</b>	<b>16%</b>		<b>10%</b>	<b>15%</b>	
<b>PAT Before Expectational Item</b>	<b>(95)</b>	<b>4</b>	<b>NM</b>	<b>(297)</b>	<b>(62)</b>	<b>NM</b>
Exceptional Item	(41)	-	NM	(20)	-	NM
<b>PAT After Expectational Item</b>	<b>(136)</b>	<b>4</b>	<b>NM</b>	<b>(317)</b>	<b>(62)</b>	<b>NM</b>

### Key Highlights for Q3 and 9M FY26

- **Revenue** growth in Q3/9M FY26 was impacted by inventory destocking in one large on-patent commercial product by customer, slower early-stage order inflows in H1FY26 due to inconsistent recovery in US biopharma funding along with uncertainties on global trade policies, and regulatory delays in inhalation anesthesia for ex-US markets from Digwal facility.
- **EBITDA Margin** – Despite lower revenues, impact on EBITDA was partly offset by our efforts towards cost optimization and operational excellence.
- **Seeing significant pick-up in RFPs with early signs of recovery in order inflows** since October 2025 on the back of improved biopharma funding and increased M&A activities in the US.
- **Growth Capex** - US\$ 90Mn investment to expand Lexington and Riverview facilities, on track. Seeing good customer interest.

**Nandini Piramal, Chairperson, Piramal Pharma Limited** said, “FY26 has been a muted year for the Company due to impact of inventory destocking and slower early-stage order inflows in H1FY26 in our CDMO business. However, in recent time, we are seeing early signs of recovery with pick-up in RFPs and order inflows on the back of improved biopharma funding and increased M&A activities in the US healthcare space. In our CHG business, we are investing in new products and expanding our presence in the ex-US markets. Acquiring niche brand like Kenalog, which is synergetic to our current business, is an important step in this direction. Our consumer business continues to outperform in its representative markets with robust growth in our power brands.

Despite the slower growth in FY26, we continue to believe in long term growth prospects of our businesses and back them with timely investments in capacities and capabilities. Q4 has been historically the strongest quarter for the Company, and we expect this trend to continue this year as well.”

## Key Business Highlights for Q3/9M FY26

### Contract Development and Manufacturing Organization (CDMO):

- **Biopharma funding in H2CY25 has shown signs of recovery** with funding in H2CY25 close to double vs. H1CY25 and higher by over 50% vs H2CY24. Although, on full year basis CY25 funding was flat vs. CY24.
- **Seeing significant improvement in RFPs along with uptick in order inflow** since October 2025. Growth in orders from both large pharma and mid-size biotech companies.
- RFP/RFI trends for our **overseas facilities with differentiated capabilities** remained healthy. These sites have superior gross margin and scale up at these facilities can drive profitability going forward.
- Sustenance of biopharma funding along with faster decision making by the customers would be the key to healthy growth in FY27.
- **US\$ 90Mn investment** to expand Lexington and Riverview facilities, on track. Seeing good customer interest for our North America sites, especially from those looking for onshoring.
- **Maintained our Best-in-Class Quality Track Record** - Successfully closed 30 regulatory inspections, including 2 USFDA inspections in 9MFY26. Continue to maintain our 'Zero OAI' status.

### Complex Hospital Generics (CHG):

- **Acquired Kenalog®** -
  - o Entered into an agreement to acquire Kenalog® from Bristol-Myers Squibb in an all-cash deal for upfront consideration of US\$ 35Mn, and contingent consideration of up to US\$ 65Mn.
  - o Kenalog® is a branded commercial injectable product with complex manufacturing requirements, complementing the CHG product portfolio. It is expected to generate EBITDA margin in-line with existing CHG business margins.
- **Inhalation Anesthesia (IA)** -
  - o Growing faster than market in the mature US Sevoflurane market with value market share of 47% - up from 44% in MAT Mar'24. (Source:- IQVIA)
  - o Initiated Sevoflurane supplies from lower cost Digwal facility in RoW markets. However initial pick-up lower than expected due to regulatory delays.
- **Intrathecal Therapy** – Supply impacted in Q2FY26 have normalized. Maintained our #1 Rank in intrathecal Baclofen in the US with 75% value market share. (Source:- IQVIA)
- **Injectable Pain Management** – Initiatives to resolve supply constraints starting to yield results.

### Piramal Consumer Healthcare (PCH):

- **Power Brands** grew strength to strength with 30% / 23% YoY growth during Q3 / 9M FY26, contributing to 51% of total PCH sales. Growth was primarily driven by Little's, Lacto Calamine, CIR, and i-range.
- **New Product Launches** – Launched 31 new products and SKUs in 9M FY26.
- Invested about 12% of PCH sales in **media and promotions** in 9M FY26.
- **E-commerce** sales grew at 50% rate YoY in 9M FY26, contributing about 26% to PCH sales. More than 40% of e-commerce sales coming from quick commerce.
- **Optimizing Portfolio and Distribution Channel Mix** - Focused efforts to grow profitable brands and distribution channels with better margins.

## Consolidated Profit and Loss Statement

*(in ₹ Crores or as stated)*

Particulars	Quarterly					Nine Months		
	Q3FY26	Q3FY25	YoY %	Q2FY26	QoQ %	9MFY26	9MFY25	YoY %
Revenue from Operations	2,140	2,204	(3)%	2,044	5%	6,117	6,397	(4)%
Other Income	43	12	256%	66	(34)%	167	93	80%
<b>Total Income</b>	<b>2,183</b>	<b>2,216</b>	<b>(2)%</b>	<b>2,109</b>	<b>3%</b>	<b>6,285</b>	<b>6,490</b>	<b>(3)%</b>
Material Cost	786	806	(2)%	703	12%	2,183	2,277	(4)%
Employee Expenses	600	556	8%	611	(2)%	1,830	1,695	8%
Other Expenses	558	504	11%	571	(2)%	1,643	1,541	7%
<b>EBITDA</b>	<b>239</b>	<b>350</b>	<b>(32)%</b>	<b>224</b>	<b>7%</b>	<b>628</b>	<b>977</b>	<b>(36)%</b>
Interest Expenses	89	103	(14)%	82	8%	258	318	(19)%
Depreciation	213	197	8%	203	5%	613	574	7%
Share of Net Profit of Associates	10	17	(40)%	15	(31)%	44	57	(23)%
<b>Profit Before Tax</b>	<b>(53)</b>	<b>67</b>	<b>NM</b>	<b>(46)</b>	<b>NM</b>	<b>(199)</b>	<b>142</b>	<b>NM</b>
Tax	42	63	(33)%	53	(20)%	98	204	(52)%
<b>Net Profit after Tax</b>	<b>(95)</b>	<b>4</b>	<b>NM</b>	<b>(99)</b>	<b>NM</b>	<b>(297)</b>	<b>(62)</b>	<b>NM</b>
Exceptional item <sup>1</sup>	(41)	-	NM	-	NM	(20)	-	NM
<b>Net Profit after Tax after Exceptional Item</b>	<b>(136)</b>	<b>4</b>	<b>NM</b>	<b>(99)</b>	<b>NM</b>	<b>(317)</b>	<b>(62)</b>	<b>NM</b>

1. Q3FY26 - Includes gratuity and leave encashment provision due to impact of change in LWF Act ₹ 26 Crs. & Settlement with CDMO customers ₹ 15 Crs.  
9MFY26 – Includes exceptional items of Q3FY26 partially offset by one time insolvency proceeds received in Q1FY26 from a claim filed against a third-party supplier of CHG by ₹ 21Crs.

## Q3 and 9M FY26 Earnings Conference Call

Piramal Pharma Limited will be hosting a conference call for investors / analysts on **29<sup>th</sup> January 2026 from 9:30 AM to 10:15 AM (IST) to discuss its Q3 and 9M FY26 Results.**

The dial-in details for the call are as under:

Event	Location & Time	Telephone Number
Conference call on 29 <sup>th</sup> January, 2026	India – 09:30 AM IST	+91 22 6280 1461 / +91 22 7115 8320 (Primary Number) 1 800 120 1221 (Toll free number)
	USA – 11:00 AM (Eastern Time – New York)	Toll free number 18667462133
	UK – 04:00 AM (London Time)	Toll free number 08081011573
	Singapore – 12:00 PM (Singapore Time)	Toll free number 8001012045
	Hong Kong – 12:00 PM (Hong Kong Time)	Toll free number 800964448
Express Join with Diamond Pass™	Please use this link for prior registration to reduce wait time at the time of joining the call – <a href="#">Click here</a>	

### About Piramal Pharma Limited:

Piramal Pharma Limited (PPL, NSE: PPLPHARMA | BSE: 543635), offers a portfolio of differentiated products and services through its 17<sup>1</sup> global development and manufacturing facilities and a global distribution network in over 100 countries. PPL includes Piramal Pharma Solutions (PPS), an integrated contract development and manufacturing organization; Piramal Critical Care (PCC), a complex hospital generics business; and Piramal Consumer Healthcare (PCH) business, selling over-the-counter consumer and wellness products. In addition, one of PPL's associate companies, Abbvie Therapeutics India Private Limited, a joint venture between Abbvie and PPL, has emerged as one of the market leaders in the ophthalmology therapy area in the Indian pharma market. Further, PPL has a strategic minority investment in Yapan Bio Private Limited, that operates in the biologics / bio-therapeutics and vaccine segments.

For more information, visit: [Piramal Pharma](#) | [LinkedIn](#)

1. Includes one facility via PPL's minority investment in Yapan Bio.

### For Investor Queries:

Gagan Borana  
Investor Relations & Enterprise Risk Management  
[gagan.borana@piramal.com](mailto:gagan.borana@piramal.com)

Madhusudan Dalmia  
Investor Relations  
[madhusudan.dalmia@piramal.com](mailto:madhusudan.dalmia@piramal.com)

### For Media Queries:

Madiha Vahid  
Lead – Branding & Communications  
[madiha.vahid@piramal.com](mailto:madiha.vahid@piramal.com)

# Q3FY26 Results

January 2026



# Piramal Pharma Limited





# Disclaimer

This presentation and the accompanying slides (the “Presentation”), which have been prepared by Piramal Pharma Limited (the “Company”), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation, directly or indirectly, in any manner, or inducement to sell or issue, or any solicitation of any offer to purchase or subscribe for any securities of the Company in any jurisdiction, and shall not form the basis or be relied on in connection with any contract or binding commitment what so ever.

Except for the historical information contained herein, statements in this Presentation and any subsequent discussions, which include words or phrases such as 'will', 'aim', 'will likely result', 'would', 'believe', 'may', 'expect', 'will continue', 'anticipate', 'estimate', 'intend', 'plan', 'contemplate', 'seek to', 'future', 'objective', 'goal', 'likely', 'project', 'on-course', 'should', 'potential', 'pipeline', 'guidance', 'will pursue' 'trend line' and similar expressions or variations of such expressions may constitute 'forward-looking statements'.

Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and other factors that could cause actual results to differ materially from those suggested by the forward-looking statements.

These risks and uncertainties include, but are not limited to Company's ability to successfully implement its strategy, the Company's growth and expansion plans, the performance of the Indian economy and of the economies of various international markets, obtain regulatory approvals, provisioning policies, technological changes, investment and business income, income or cash flow projections, the performance of the industry in India and world-wide, exposure to market risks as well as other risks. The Company's actual results, levels of activity, performance or achievements could differ materially from results expressed in or implied by this Presentation.

Company does not undertake any obligation to update forward-looking statements to reflect events or circumstances after the date thereof. Any forward-looking statements and projections made by third parties included in this Presentation are not adopted by the Company and the Company is not responsible for such third party statements and projections. Given these uncertainties and other factors, viewers of this Presentation are cautioned not to place undue reliance on these forward-looking statements. The information in this Presentation does not constitute financial advice (nor investment, tax, accounting or legal advice) and does not take into account an investor's individual investment objectives, including the merits and risks involved in an investment in the Company or its securities, or an investor's financial situation, tax position or particular needs. Past performance information in this Presentation should not be relied upon as an indication of (and is not an indicator of) future performance.

This Presentation is not a prospectus, disclosure document, a statement in lieu of a prospectus, an offering circular, an invitation or an advertisement or an offer document under the Companies Act, 2013, together with the rules and regulations made thereunder, as amended, the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2018, as amended, or any other applicable law in India. This Presentation has been prepared by the Company based on information and data which the Company considers reliable, but the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation, and nothing in this Presentation shall be relied upon as a promise or representation in this respect, whether as to the past or the future. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. The Presentation has not been independently verified and any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded.

The contents of this Presentation are strictly confidential and may not be copied or disseminated, reproduced, re-circulated, published, advertised or redistributed, in whole or in part, to any other person or in any media, website or otherwise in any manner without the Company's written consent.

Note: Figures in previous periods might have been regrouped or restated, wherever necessary to make them comparable to current period. For the ease of presentation, certain financial information herein has been rounded off to one decimal place or two decimal places or whole numbers, as the case may be.

# Piramal Pharma – A Diversified Global Pharma & Wellness Company



A Portfolio of Differentiated Products and Services, and Commercial Presence in 100+ Countries

## CDMO Business

### Integrated CDMO Company

- **15** - Manufacturing and development sites across US, Europe, Canada, and India.
- **140+** - Molecules under development with **30+** molecules in Phase III.
- **54%** - Share of Innovation related work.
- **49%** revenues from differentiated offerings – ADC, HPAPI, Sterile Injectables, Peptides, On-patent API Development & Manufacturing.
- **120+** Integrated projects executed.

## Complex Hospital Generics Business

### A Critical Care Company




- **One of the leading** Inhalation Anesthesia companies in the world.
  - **#1** - Rank in US sevoflurane market with **47%** market share.
  - **Vertically integrated** manufacturing
- **#1** - Rank in US Intrathecal Baclofen market with about **75%** market share.
- Commercial presence in **100+** countries and **6,000+** hospitals.

## Consumer Healthcare Business

### Consumer Health & Wellness Company

- **Self-funded** and asset light business model with annual revenue of over ₹ 1,000 Crs.
- **25+ Brands** – Diversified portfolio across high growth segments.
  - **6** - Power Brands growing at ~20% CAGR
- **Multichannel distribution network**
  - **180k+** - Chemists and cosmetics shops.
  - **20+** - Presence on e-commerce platforms.

(In ₹ Crore)









# Performance Highlights

---

# Key Financial Highlights – Q3 / 9M FY26

## Revenue from Operations



(In ₹ Crore)



## EBITDA & EBITDA Margin

(EBITDA: In ₹ Crore)

EBITDA Margin



## Summary

**Revenue and EBITDA growth** during Q3 and 9M FY26 was impacted by:

- Inventory destocking in one large on-patent commercial product by customer.
- Slower early-stage order inflows in H1FY26 due to inconsistent recovery in US biopharma funding along with uncertainties on global trade policies.
- Regulatory delays in inhalation anesthesia for ex-US markets from Digwal.

**Seeing significant pick-up in RFPs with early signs of recovery in order inflows** since Oct'25 on the back of improved biopharma funding and increased M&A activities in the US.

**Q4 is historically the strongest quarter** for the Company, driven by the CDMO business.

**Expect this trend to continue this year as well.**

# Strengthening Our Core

**Despite a Challenging Year, We Continue to Build on Our Strengths for a Stronger Future**

## Key Initiatives Taken

CDMO

### Investing In High Growth Areas

Investing US\$90mn to scale **sterile injectable and payload-linker** capacities at Lexington & Riverview. Seeing encouraging customer interest.

### Enhanced our Business Development team

Adapt to market dynamics & better engage with customers. Seeing **pick-up in order inflows** – from both large pharma and mid-size biotech.

### Strengthened Execution Across Network

Ensure **customer delight** & win repeat business. Improvement in customer satisfaction score helps in **cross selling**. Achieved a Net Promoter Score of 55, surpassing industry average.

### Continued Focus on Quality & Sustainability

**Zero OAs. Zero Fatalities.** YoY Increase in sustainability scores across different rating agencies.

CHG

### Differentiated and Specialty Products

**Entered into Agreement to Acquire Kenalog®** from Bristol-Myers Squibb. Adds new lever of revenue without significant incremental cost, especially in the US, Europe & Asia pacific, with healthy EBITDA margin.

### Commercialized Sevoflurane from India

Initiated **Sevoflurane supplies** from lower cost **Digwal facility**. Should help expand our market share in price sensitive ex-US markets.

### Supply Assurance for Injectable Pain Management

**Initiatives to improve supplies** of Injectable Pain Management portfolio. Should help defend and grow market share.

# Strengthening Our Core

**Despite a Challenging Year, We Continue to Build on Our Strengths for a Stronger Future**

## Key Initiatives Taken

### Continued to Invest in Our Power Brands

**Strong growth of 20%+ in Power Brands** led by advertising and brand building support, and regular new product and SKU launches to leverage mother brands.

### Expanding Reach into Tier 3/4 Towns

Accelerated expansion into **Tier 3/4 towns** in General Trade while also expanding our presence in **Modern Trade**.

### Optimizing Portfolio and Distribution Channel Mix

To drive **revenue growth along with better profitability** – Focused efforts to grow profitable brands and distribution channels with better margins.



*These initiatives along with improving macro environment conditions (better biopharma funding, increased M&A activities, etc.) should help us deliver a turnaround performance in quarters ahead.*





# Business Wise Performance

---

## Performance Highlights

### ❖ Biopharma funding showing signs of improvement

- **Strong recovery in biopharma funding in H2CY25** - Funding in H2CY25 was close to double vs. H1CY25 and higher by over 50% vs. H2CY24. (Source: Industry Reports)
- Although, on a full year basis biopharma funding for CY25 was flat compared to CY24.
- Sustained funding momentum to act as catalyst for growth in order inflows.

### ❖ Witnessing meaningful uptick in RFPs and order inflow since October 2025

- YoY pick-up in orders from both large pharma and mid-size biotech companies.
- RFP/RFI trends for our **overseas facilities with differentiated capabilities** remained healthy. Scale up in revenues at these facilities to drive profitability going forward.

### ❖ YoY performance during Q3 and 9M FY26


- **Impacted by slower early-stage discovery and development order inflows in H1FY26** due to inconsistent recovery in US biopharma funding along with uncertainties on global trade policies leading to adverse impact on order inflow and customer decision making.
- Despite lower revenues, impact on EBITDA was partly offset by our efforts towards **cost optimization and operational excellence**.

## Revenue Growth

(In ₹ Crore)

▼ (12)%


▼ (9)%






# Maintaining our Best-in-Class Quality Track Record

## 400+ Regulatory Inspections with no OAI



## 150+ Audits Annually by Customers



- ❖ Successfully cleared 48 US FDA inspections, 407 total regulatory inspections and 2,081 customer audits since FY2012
- ❖ Successfully cleared 30 regulatory inspections and 170 customer audits in 9MFY26
- ❖ No 'Official Action Indicated (OAI)' for any of our US FDA audits

# US Expansion on Track – Seeing Good Customer Interest

## Steadily Increasing our Footprint in the US



Ongoing expansion in Lexington



Riverview – Payload linker expansion



Sellersville - Joint investment with NewAmsterdam Pharma

**US\$ 90Mn investment** to expand **Lexington** and **Riverview** facilities, on track. Seeing good customer interest for our North America (NA) sites. **Our NA sites with differentiated capabilities have superior gross margin profile, which at optimum revenue scale can deliver healthy EBITDA margins.**

- **Lexington:-** Adding commercial-scale sterile injectables capacity to increase output from 104 to 240+ batches annually. The upgrade will enhance efficiency and strengthen support for rising market demand
- **Riverview:-** New commercial-scale suite for **payload-linker** development & manufacturing. This is in addition to our earlier investments totaling **US\$ 60Mn in Riverview and Aurora** towards increasing our capacity for **APIs, HP APIs, and payload-linkers**

**Sellersville:-** Multi-million-dollar **joint investment** with NewAmsterdam Pharma to **provide commercial capacity** for fixed dose combination of Obicetrapib and Ezetimibe to meet commercial demand

**Sites to benefit from clients looking for onshoring in North America**

## Our Presence in the US

**3**

Manufacturing and Development Sites

**~US\$ 200Mn**

Investment in US

**450+**

Employees

**HP API, Sterile Injectable, API, Formulation**

Capabilities

**USFDA, EMA, PMDA, HC**

Major Regulatory Accreditation

# Complex Hospital Generics Business

## Performance Highlights

### ❖ Inhalation Anesthesia

- **US** - Continue to grow ahead of the market and maintain **#1 Rank in Sevoflurane** with value market share of 47% - up from 44% in Mar'24. (Source:- IQVIA)
- **Ex-US Markets** – Initiated Sevoflurane supplies from lower cost Digwal facility. However initial pick-up lower than expected due to regulatory delays.

### ❖ Intrathecal Therapy

- Continue to maintain our **#1 Rank** in intrathecal Baclofen segment in the US with about **75%** value market share. (Source:- IQVIA)
- Supplies impacted in Q2FY26 have normalized.


### ❖ Injectable Pain Management – Initiatives to resolve supply constraint starting to yield results.

### ❖ Differentiated and Specialty Products

- Continue to invest in 505(b)(2)'s, complex generics, differentiated generics, and branded products through in-licensing deals or co-development projects to enable long term growth.

## Revenue Growth

(In ₹ Crore)



# Agreement to Acquire Kenalog® from Bristol-Myers Squibb

**Complex Product with Limited Competition and Healthy EBITDA margins – A Good Fit for Our CHG Portfolio**

Entered into an agreement to acquire **Kenalog® from Bristol-Myers Squibb Company in an all-cash deal** for upfront consideration of US\$ 35Mn, and an additional contingent consideration of up to US\$ 65Mn on achieving certain agreed operational and financial milestones.

The acquisition will also help us **broaden our CHG portfolio, add revenues without significant incremental cost**, and grow our presence in key markets like the US, Europe & Asia pacific.

The Brand is expected to generate **EBITDA margin in-line with existing CHG** business margins and its attractive niche with complex manufacturing requirements complements the business portfolio.

Despite losing exclusivity more than 30 years ago, the product has limited competition in most of its existing key markets.



Kenalog®, a **branded commercial injectable product** containing Triamcinolone Acetonide, is a synthetic corticosteroid with anti-inflammatory, antipruritic action & antiallergic action and indicated as adjunctive therapy in acute gouty, rheumatoid arthritis, and other conditions to treat inflammation.

# Piramal Consumer Healthcare Business


## Performance Highlights

- ❖ **Strong growth of 20%/16%** in Q3 and 9M FY26 – **faster than market**
- ❖ **Power Brands grew strength to strength at 30%/23%** in Q3 and 9MFY26
  - Contributing 51% to total PCH sales in 9M FY26
  - Growth was driven by Little's, Lacto Calamine, CIR, and i-range
- ❖ **E-commerce sales** grew at 63%/50% in Q3 and 9M FY26
  - Contributing 28%/26% to PCH sales in Q3 and 9M FY26
  - 40%+ of e-commerce sales coming from quick commerce
- ❖ **Advertisement spends in 9M FY26 at 12%** of PCH sales
- ❖ **New product launches** – 31 new products and SKUs launched in 9MFY26. Products launched in last 24 months contributed 8% to PCH sales in FY25.




## Revenue Growth

(In ₹ Crore)







# Focus on Power Brands with Brand Promotion and Marketing



## Investments in Brand Promotion and Marketing



## Strong Growth in our Power Brands





# Joint Venture with AbbVie

AbbVie Therapeutics India Private Limited, a joint venture between AbbVie and PPL, is one of the market leaders in the Indian ophthalmology therapy area



In FY2025, the JV reported revenue of ₹494 Cr. with PAT margin of 28%

**Brand** ▶  
**Segment** ▶



**Lumigan**  
**Glaucoma**



**Combigan**  
**Glaucoma**



**Refresh Tears**  
**Dry Eyes**



**Alphagan**  
**Glaucoma**



**Pred Forte**  
**Eye Inflammation**



# Financials

---

# Consolidated Financials Highlights

(in ₹ Cr. or as stated)

Particulars	Q3FY26	Q3FY25	YoY Change	Q2FY26	QoQ Change	9MFY26	9MFY25	YoY Change
<b>Revenue from Operations<sup>1</sup></b>	<b>2,140</b>	<b>2,204</b>	<b>(3)%</b>	<b>2,044</b>	<b>5%</b>	<b>6,117</b>	<b>6,397</b>	<b>(4)%</b>
CDMO	1,166	1,278	(9)%	1,044	12%	3,207	3,659	(12)%
CHG	668	654	2%	644	4%	1,948	1,928	1%
PCH	334	278	20%	319	5%	954	819	16%
<b>EBITDA</b>	<b>239</b>	<b>350</b>	<b>(32)%</b>	<b>224</b>	<b>7%</b>	<b>628</b>	<b>977</b>	<b>(36)%</b>
<b>EBITDA Margin</b>	<b>11%</b>	<b>16%</b>		<b>11%</b>		<b>10%</b>	<b>15%</b>	
Share of Net Profit of Associates	10	17	(40)%	15	(31)%	44	57	(23)%
<b>PAT (before exceptional items)</b>	<b>(95)</b>	<b>4</b>	<b>NM</b>	<b>(99)</b>	<b>NM</b>	<b>(297)</b>	<b>(62)</b>	<b>NM</b>
Exceptional Item <sup>2</sup>	(41)	-	NM	-	NM	(20)	-	NM
<b>PAT (after exceptional items)</b>	<b>(136)</b>	<b>4</b>	<b>NM</b>	<b>(99)</b>	<b>NM</b>	<b>(317)</b>	<b>(62)</b>	<b>NM</b>

1. Revenue from Operations includes foreign exchange gains/losses

2. Q3FY26 - Includes gratuity and leave encashment provision due to impact of change in LWF Act ₹ 26 Crs. & Settlement with CDMO customers ₹ 15 Crs.

9MFY26 – Includes exceptional items of Q3FY26 partially offset by one time insolvency proceeds received in Q1FY26 from a claim filed against a third-party supplier of CHG by ₹ 21Crs.



# Sustainability


---



# Strengthening Sustainability Performance - External Validation

Rising Sustainability scores reflect consistent execution against science-based targets and responsible operations

## Sustainability Ratings: Demonstrated Improvement & Expanding Coverage



Continuous improvement across leading ESG assessment frameworks reinforce Company's sustainability maturity.

## Science-Based Targets initiative (SBTi Approved)



**SBTi-approved decarbonisation roadmap** across operations and value chain.



**42%** reduction in absolute Scope 1 & 2 emissions by FY2030  
(Baseline: FY2022)



**25%** reduction in Scope 3 emissions aligned with SBTi methodology by FY2030  
(Baseline: FY2022)

Our progress on the sustainability ratings underscores our unwavering dedication to responsible operations and sustainable growth. As we continue to expand, we remain committed to excellence in every aspect of our work, ensuring our work contributes to a healthier future for all.

Peter DeYoung, CEO Global Pharma

# Embedding Sustainability in Every Step of Our Growth



## Responsible Operations

**Zero**

Hazardous Waste to Landfill

**2.10 Lakh**

Kiloliters of Freshwater  
Saved

**10.5%**

Reduction in Scope 1 & 2  
Emissions Over Base Year  
(FY22)

**14.08%**

Total Energy Sourced from Bio-  
Briquettes/Biomass



## Business Resilience

**50%**

Independent Directors  
on the Board

**100%**

Workforce Trained on Code of  
Conduct

**26.5%**

Of critical Suppliers Assessed  
on ESG

**Zero**

Cases of Data Breaches/  
Corruption Incidents



## Quality and Excellence

**36**

Successful Regulatory  
Inspections

**165**

Successful Customer Audits

**2**

Successful USFDA  
Inspections

**17**

KPI Dashboards to Digitalise  
Governance



## Stakeholder Centricity

**20%**

Of the Global Workforce are  
Women

**65/100**

EcoVadis Score  
(Bronze Medal)

**Zero**

Fatalities in the Last Four  
Years

**0.05**

Loss Time Injury Rate



# Dial-in Details for Q3 and 9M FY26 Earnings Conference Call

Event	Location & Time	Telephone Number
Conference call on 29 <sup>th</sup> January 2026	India – 09:30 AM IST	+91 22 6280 1461 / +91 22 7115 8320 (Primary Number)
		1 800 120 1221 (Toll free number)
	USA – 11:00 PM (Eastern Time – New York)	Toll free number 18667462133
	UK – 04:00 AM (London Time)	Toll free number 08081011573
	Singapore – 12:00 PM (Singapore Time)	Toll free number 8001012045
	Hong Kong – 12:00 PM (Hong Kong Time)	Toll free number 800964448
Express Join with Diamond Pass™	Please use this link for prior registration to reduce wait time at the time of joining the call – <a href="#">Click here</a>	

## For Investor Queries:

### **Gagan Borana**

**Investor Relations and Enterprise Risk Management**

Email: [gagan.borana@piramal.com](mailto:gagan.borana@piramal.com)



### **Madhusudan Dalmia**

**Investor Relations**

Email: [madhusudan.dalmia@piramal.com](mailto:madhusudan.dalmia@piramal.com)



## Our Websites:-

### **Piramal Pharma Limited**

[www.piramalpharma.com](http://www.piramalpharma.com)

### **Complex Hospital Generics**

[www.piramalcriticalcare.com](http://www.piramalcriticalcare.com)

### **CDMO**

[www.piramalpharmasolutions.com](http://www.piramalpharmasolutions.com)

### **Piramal Consumer Healthcare**

[www.wellify.in](http://www.wellify.in)